CureGN

治愈GN

• 批准号: 10467441
• 负责人: BRENDA W GILLESPIE
• 金额: $ 15万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-23 至 2024-05-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10467441
• 关键词: Ancillary Study; Biological Markers; Biology; Blood; Clinical Data; Clinical Research; Communities; DNA; Data Set; Disease; Focal Segmental Glomerulosclerosis; Funding; Genetic; Genetic study; Genomics; IGA Glomerulonephritis; Infrastructure; Kidney Diseases; Link; Logistics; Membranous Glomerulonephritis; National Institute of Diabetes and Digestive and Kidney Diseases; Natural History; Participant; Patients; Process; Quality Control; RNA; Renal glomerular disease; Resources; Sampling; Scientist; Services; Ships; Therapeutic; Translational Research; Visit; biobank; cohort; cost; digital repositories; disease heterogeneity; disease natural history; ethnic diversity; genetic information; improved; international center; kidney biopsy; precision medicine; recruit; service providers

ABSTRACT Cure Glomerulonephropathy (CureGN) is a National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)-sponsored, multi-center international consortium established in 2013 to study the natural history of glomerular diseases (minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, and IgA nephropathy), understand their underlying biology, develop biomarkers to resolve disease heterogeneity, and ultimately improve therapeutic options. CureGN has made progress in: 1) establishing a large, ethnically diverse longitudinal observational cohort of glomerular disease patients; 2) creating a rich, well-curated clinical data set and linked biospecimens; 3) establishing the largest repository of digital kidney biopsies; and 4) an infrastructure that will facilitate translational and clinical research by core and ancillary study scientists. Defining the genetic and genomic landscape of the diseases studied by CureGN has been a core aim from the initiation of the study and the emerging genetic information of CureGN participants is currently utilized by a multitude of core and ancillary studies. As CureGN will continue to recruit a limited set of patients, the blood biospecimens from the enrollemtn visit will need to be processed so that isolated DNA and RNA can be submitted to the NIDDK central biorepository for use by the scientific community. This supplemental funding request asked to cover the isolation costs for up to 1000 patients (200 patients already recruited, and up to 800 to be recruited depending on the recruit to replace needs of CureGN 2). CureGN will use a centralized service by Precision for Medicine who has an outstanding track record for processing excellence and quality control metrics in place. This service provider will also be able to access the biosamples from the incoming CureGN shipments to the NIDDK CBR, reducing sample transfer logistical burden and opportunity for sample losses substantially.

抽象的 Cure 肾小球肾病 (CureGN) 是国家糖尿病、消化和肾脏研究所 疾病 (NIDDK) 赞助的多中心国际联盟于 2013 年成立，旨在研究自然疾病 肾小球疾病史（微小病变、局灶节段性肾小球硬化症、膜性肾病） 肾病和 IgA 肾病），了解其基础生物学，开发生物标志物来解决 疾病异质性，并最终改善治疗选择。 CureGN 在以下方面取得了进展：1) 建立一个大型的、种族多样化的肾小球疾病患者纵向观察队列； 2） 创建丰富、精心策划的临床数据集和链接的生物样本； 3）建立最大的存储库 数字肾活检； 4) 基础设施将促进核心和临床研究的转化和临床研究 辅助研究科学家。 定义 CureGN 研究的疾病的遗传和基因组景观一直是 CureGN 的核心目标 研究的启动和 CureGN 参与者的新出现的遗传信息目前被 大量的核心和辅助研究。 由于 CureGN 将继续招募有限的患者，因此来自登记访视的血液生物样本 需要进行处理，以便将分离的 DNA 和 RNA 提交至 NIDDK 中央生物样本库 供科学界使用。 该补充资金请求要求支付最多 1000 名患者（200 名患者）的隔离费用 已招募，并且根据替换 CureGN 的需要招募最多 800 名 2)。 CureGN 将使用 Precision for Medicine 的集中服务，该公司在以下方面拥有出色的记录： 卓越的加工和到位的质量控制指标。该服务提供商还可以访问 将生物样本从传入的 CureGN 货物运送到 NIDDK CBR，从而减少样本转移的物流 样品损失的负担和机会。